for T1 cancers where traditionally prognosis is good:
http://www.annalssurgicaloncology.or...t/11/6/568.pdf
http://clincancerres.aacrjournals.or...act/12/22/6696
PS The above studies are interesting because they have lont-term follow-up of 8 and 15 years.
And a divergent opinion, where LVI positivity had more importance, in a SMALL study of 8 year follow-up: (PS not sure I give this same study much stock , especially since the decision of adj. therapy may be a life-saving one.)
http://www.blackwell-synergy.com/doi...X.2006.00267.x
To sum it up, overall, micromets and ITC in the sentinel appears to have a play in long-term relapse, and adjuvant therapy may have a role in relapse prevention.
Adj. tx. guidelines are for t1a lesions are aggressive, even without positive lymph node because, "Patients with high-grade tumors and/or LVI may have<sup> </sup>10-year RFS rates of less than 75% in the absence of systemic<sup> </sup>therapy. "...
http://jco.ascopubs.org/cgi/content/abstract/24/13/2113